To: jmhollen who wrote (244) | 3/7/2005 9:40:04 AM | From: BiotaBull | | | Buy BIOTA on the ASX Australian market. They have the major anti-viral drug Relenza, the biggest competitor is Roche's Tamiflu. Biota is very likely to win the case against Glaxo... I lost my id details when SI changes everything, I was a life-time member since 1998! I used to be RAJA... now i have to start again.! |
| GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: BiotaBull who wrote (247) | 3/8/2005 8:29:42 PM | From: Tadsamillionaire | | | Further tests reveal more human bird flu cases in Vietnam Tue Mar 8, 9:14 AM ET Health - AFP HANOI (AFP) - Seven Vietnamese patients who had initially tested negative for bird flu have been found to have carried the virus, the World Health Organisation said after further tests by a laboratory in Tokyo. news.yahoo.com
THE death toll from a bird flu pandemic in Scotland could hit 200,000, a leading scientist has predicted. ragingbull.lycos.com
GENOMED on Career builder.com GenoMed, Inc. a start-up disease management and biotech company located in St. Louis, MO, invites applications for its full-time Research Technician position. You would be responsible, under the direction of the Chief Scientific Officer, to conduct research, to maintain all laboratory equipment and to order supplies, plus other duties as indicated.Must be flexible and a team player. We are a small company with a tremendous amount of potential—come join the future of genomic medicine makeashorterlink.com |
| GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
From: Tadsamillionaire | 3/8/2005 8:34:05 PM | | | | WHO: Bird flu pandemic is imminent Governments must act swiftly to prevent outbreak, officials say World Health Organization officials urged governments on Wednesday to act swiftly to control the spread of bird flu, warning that the world is in grave danger of a deadly pandemic triggered by the virus.The illness has killed 45 people in Asia over the past year, in cases largely traced to contact with sick birds, and experts have warned the H5N1 virus could become far deadlier if it mutates into a form that can be easily transmitted among humans. A global pandemic could kill millions, they say.
“We at WHO believe that the world is now in the gravest possible danger of a pandemic,” Dr. Shigeru Omi, the WHO’s Western Pacific regional director, said Wednesday.
He said the world is “now overdue” for an influenza pandemic, since mass epidemics have occurred every 20 to 30 years. It has been nearly 40 years since the last one.
Better coordination critical Speaking at the opening of a three-day bird flu conference in Vietnam's Ho Chi Minh City, Omi said it is critical that the international community better coordinate its fight against the virus.
As bird flu experts met to devise plans to combat the H5N1 virus, scientists said they lacked knowledge about whether the strain that has led to the slaughter of tens of millions of birds has the pandemic potential of the 1918 Spanish flu that killed between 20 million and 40 million people.
They cautioned that more evidence is needed about how infectious the virus is in humans.
To become a pandemic strain, H5N1 would have to adapt sufficiently on its own, or mix its genetic material with a human virus to become highly infectious in humans who have no protection against it.
“We don’t know whether the virus that is currently circulating among poultry in southeast Asia, the H5N1, will eventually be able to reassert its genetic material with a human influenza virus. That is the key question,” Professor Albert Osterhaus, a leading European virologist at Erasmus University Hospital in Rotterdam, told Reuters in an interview.
msnbc.msn.com |
| GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
To: BiotaBull who wrote (251) | 3/14/2005 11:09:15 PM | From: Tadsamillionaire | | | GenoMed, Inc. Says New Medicare Legislation May Accelerate Acceptance of Its Therapy ST LOUIS, March 10 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News) said today that recently adopted legislation allowing pharmacists to take an expanded role in providing healthcare could accelerate acceptance of the company's treatment protocol for a number of diseases.The company said the adoption by Congress of the Medicare Modernization Act allows a pharmacist, under a doctor's supervision, to help manage patients' medications. It provides compensation to the pharmacists for services such as checking blood pressure and adjusting blood pressure medication.
"This is potentially an important development for GenoMed," said GenoMed CEO and chief medical officer David W. Moskowitz. "One of the obstacles to the broad acceptance of our treatment protocol has been the difficulty patients encounter in obtaining appointments with their physician. In the startup phase of our protocol, relatively frequent appointments are needed to take blood pressure and adjust the drug dosage of ACE inhibitor, which is the core of our treatment. That has been difficult because physicians are so busy that seeing them every two weeks is often impossible. Now that the difficulty of adopting our treatment can be easier, patients may be more willing to enroll."
"Our patent-pending protocols to arrest or prevent diabetes, high blood pressure and other diseases are ideal for the nation's 55,000 retail pharmacists. They can work closely with physicians and GenoMed while seeing patients with the frequency needed to gather and provide the necessary data to titrate the dosage. Since under the new law pharmacists are able to receive compensation for services like taking blood pressure and adjusting medication, they should be willing to participate," Moskowitz said.
Moskowitz, speaking earlier this week at the 28th annual conference of the National Council of Prescription Drug Plans said GenoMed's data has demonstrated that ACE inhibitors can prevent kidney failure in patients with diabetes or high blood pressure. ACE inhibitors are a commonly prescribed drug that, as their name implies, inhibits the action of the ACE gene. GenoMed's research has identified ACE as a "master disease gene" linked to the development of a large number of common diseases.
Moskowitz noted that other speakers at the conference agreed that prescription drugs are the best value in health care. Properly used, they can eliminate hospitalization, which is far more expensive. They can also prevent the onset of many diseases that, once contracted, require ongoing and expensive treatment.
Several of the large Pharmacy Benefit Management organizations represented at the conference expressed an interest in the GenoMed protocol because it employs drugs that are available in generic form. These organizations have been strong advocates of the use of generic drugs to help control healthcare costs.
"We believe the Medicare Modernization Act provides us with an opportunity to accelerate the acceptance of our protocol. The interest expressed by various entities in using GenoMed's treatment, combined with the economic incentives now available to retail pharmacists make it easier for patients to participate. We are actively pursuing this opportunity and are encouraged by the more favorable environment," Moskowitz said.
biz.yahoo.com |
| GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
From: jmhollen | 3/24/2005 5:15:30 PM | | | | GenoMed's Dr. David Moskowitz Featured on Wall Street Reporter; Says GenoMed Set to Improve Nation's Public Health March 24, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that its Chairman and CEO, Dr. David Moskowitz, is featured in Wall Street Reporter Magazine discussing how preventive molecular medicine as GenoMed practices it can significantly lower healthcare costs.
wallstreetreporter.com GenoMed also participated in a recent Genomics Roundtable hosted by the Wall Street Reporter Magazine, available at:
wallstreetreporter.com
GenoMed has aligned its business model with optimizing public health. The Company's goal is to find the least expensive, fastest, and safest way to improve patient outcomes. The Company has already accomplished this for diabetes, hypertension, and emphysema, which affect over 85 million Americans. This summer GenoMed will again conduct a free national trial for West Nile virus using already existing, FDA-approved drugs.
GenoMed's business model is ideal for today's political climate. It is tailor-made for Health Savings Accounts (HSA's) and Consumer-Directed Health Care (CDHC). In addition to educating health plans about its Next Generation DM(tm) services, GenoMed is also encouraging patients who control their own Health Savings Account to sign up themselves for GenoMed's modestly priced services.
About GenoMed
GenoMed has already found what it believes is the major gene for aging. Using this information, GenoMed has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics, dramatically delay the progression of terminal emphysema, and treat autoimmune diseases and cancer. GenoMed has recently found several thousand genes for the top six solid cancers--breast, colon, lung, ovarian, pancreatic, and prostate--and expects to have new diagnostic and therapeutic tools ready for clincal trials soon. . |
| GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |